FDA lifts partial clinical hold on Blueprint Medicine cancer candidate BLU-222
hapabapa
- The US FDA has lifted a partial clinical hold placed in February on Blueprint Medicines' (NASDAQ:BPMC) early stage candidate BLU-222 for CDK2-vulnerable cancers.
- The hold was due to visual adverse events, such as short lasting, reversible episodes of light sensitivity and blurred vision seen in a few patients.
- Blueprint (BPMC) plans on presenting initial dose escalation data from the phase 1/2 VELA trial in Q2.
- Company shares are up 3.5% in after-hours trading.
- Read why Seeking Alpha contributor Stephen Ayers just initiated a buy rating on Blueprint (BPMC).